JP2016520653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520653A5 JP2016520653A5 JP2016518015A JP2016518015A JP2016520653A5 JP 2016520653 A5 JP2016520653 A5 JP 2016520653A5 JP 2016518015 A JP2016518015 A JP 2016518015A JP 2016518015 A JP2016518015 A JP 2016518015A JP 2016520653 A5 JP2016520653 A5 JP 2016520653A5
- Authority
- JP
- Japan
- Prior art keywords
- acamprosate
- pharmaceutical composition
- prazosin
- dose
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960004047 acamprosate Drugs 0.000 claims description 88
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 88
- 238000000034 method Methods 0.000 claims description 71
- 239000000203 mixture Substances 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 229920000642 polymer Polymers 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 18
- 235000020925 non fasting Nutrition 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 16
- 229960001157 acamprosate calcium Drugs 0.000 claims description 6
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims description 6
- 238000000338 in vitro Methods 0.000 claims description 6
- 208000024891 symptom Diseases 0.000 claims description 6
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims 26
- 229960001289 prazosin Drugs 0.000 claims 26
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 6
- 238000011269 treatment regimen Methods 0.000 claims 6
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 5
- 239000007916 tablet composition Substances 0.000 claims 5
- 229960001631 carbomer Drugs 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 238000007922 dissolution test Methods 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 3
- 208000019906 panic disease Diseases 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 208000001953 Hypotension Diseases 0.000 claims 2
- 230000036543 hypotension Effects 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 208000033712 Self injurious behaviour Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 229940075508 carbomer homopolymer type b Drugs 0.000 claims 1
- 229940096529 carboxypolymethylene Drugs 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000007906 compression Methods 0.000 claims 1
- 230000006835 compression Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 229920001519 homopolymer Polymers 0.000 claims 1
- 239000000416 hydrocolloid Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229920001285 xanthan gum Polymers 0.000 claims 1
- 239000000230 xanthan gum Substances 0.000 claims 1
- 229940082509 xanthan gum Drugs 0.000 claims 1
- 235000010493 xanthan gum Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 230000036470 plasma concentration Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 10
- 239000002552 dosage form Substances 0.000 description 5
- 230000000561 anti-psychotic effect Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 229960000607 ziprasidone Drugs 0.000 description 3
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 3
- 235000020937 fasting conditions Nutrition 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical group C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical group CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- BATFHSIVMJJJAF-UHFFFAOYSA-N Morindone Chemical compound OC1=CC=C2C(=O)C3=C(O)C(C)=CC=C3C(=O)C2=C1O BATFHSIVMJJJAF-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 229960005245 asenapine Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960004341 escitalopram Drugs 0.000 description 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 229960003162 iloperidone Drugs 0.000 description 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
- 229960000423 loxapine Drugs 0.000 description 1
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 description 1
- 229960001432 lurasidone Drugs 0.000 description 1
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 229960000600 milnacipran Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960005017 olanzapine Drugs 0.000 description 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
- 229960001057 paliperidone Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229960004431 quetiapine Drugs 0.000 description 1
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
- 229960001534 risperidone Drugs 0.000 description 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 229960005013 tiotixene Drugs 0.000 description 1
- -1 trifloperazine Chemical compound 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361831587P | 2013-06-05 | 2013-06-05 | |
| US61/831,587 | 2013-06-05 | ||
| PCT/US2014/041186 WO2014197744A1 (en) | 2013-06-05 | 2014-06-05 | Acamprosate formulations, methods of using the same, and combinations comprising the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019050939A Division JP6824314B2 (ja) | 2013-06-05 | 2019-03-19 | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520653A JP2016520653A (ja) | 2016-07-14 |
| JP2016520653A5 true JP2016520653A5 (https=) | 2017-11-09 |
Family
ID=52008600
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016518015A Pending JP2016520653A (ja) | 2013-06-05 | 2014-06-05 | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 |
| JP2019050939A Active JP6824314B2 (ja) | 2013-06-05 | 2019-03-19 | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019050939A Active JP6824314B2 (ja) | 2013-06-05 | 2019-03-19 | アカンプロサート製剤、それを用いる方法、およびそれを含む合剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US10166207B2 (https=) |
| EP (2) | EP3878445A3 (https=) |
| JP (2) | JP2016520653A (https=) |
| CN (1) | CN105431144A (https=) |
| CA (1) | CA2914365C (https=) |
| WO (1) | WO2014197744A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
| SG11201708393UA (en) * | 2015-05-04 | 2017-11-29 | Confluence Pharmaceuticals Llc | Sprinkle formulations of acamprosate |
| ES2769286T3 (es) | 2016-12-20 | 2020-06-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina |
| WO2018115010A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
| CN108785293A (zh) * | 2017-04-28 | 2018-11-13 | 天津国际生物医药联合研究院 | 阿坎酸钙在抗sars冠状病毒感染中的应用 |
| IL270654B2 (en) | 2017-05-17 | 2024-07-01 | Confluence Pharmaceuticals Llc | Formulations of homotaurines and salts thereof |
| ES2881783T3 (es) | 2017-06-26 | 2021-11-30 | Lts Lohmann Therapie Systeme Ag | Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona |
| EP3501504A1 (en) * | 2017-12-22 | 2019-06-26 | Pharmacia Polonica sp. z o.o. | Modified release tablet of paliperidone and a process for the preparation thereof |
| CN112533593A (zh) | 2018-06-20 | 2021-03-19 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| CA3101420A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
| EP3946303A4 (en) * | 2019-04-03 | 2022-12-14 | Synchroneuron Inc. | FORMULATING |
| BE1026955B1 (fr) * | 2019-06-11 | 2020-08-04 | Synapharm Ind Synthesis | Procédé de fabrication de N-acétyl-taurinate de magnésium |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3574820A (en) | 1968-01-08 | 1971-04-13 | Upjohn Co | Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| CH582002A5 (https=) | 1972-06-09 | 1976-11-30 | Purdue Research Foundation | |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US3944064A (en) | 1973-10-26 | 1976-03-16 | Alza Corporation | Self-monitored device for releasing agent at functional rate |
| US3901232A (en) | 1973-10-26 | 1975-08-26 | Alza Corp | Integrated device for administering beneficial drug at programmed rate |
| GB1478759A (en) | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4063064A (en) | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
| US4207890A (en) | 1977-01-04 | 1980-06-17 | Mcneilab, Inc. | Drug-dispensing device and method |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4339428A (en) | 1980-08-18 | 1982-07-13 | Bristol-Myers Company | Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component |
| US4690620A (en) | 1980-08-19 | 1987-09-01 | Karl Eickmann | Variable radial piston pump |
| US4434153A (en) | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
| US4536403A (en) | 1984-06-06 | 1985-08-20 | Rooks J F Girard | Method for treating neuroleptic induced tardive dyskinesia |
| JPS6143108A (ja) | 1984-08-03 | 1986-03-01 | Nippon Shinyaku Co Ltd | 医薬品製剤及びその製造法 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| GB8507779D0 (en) | 1985-03-26 | 1985-05-01 | Fujisawa Pharmaceutical Co | Drug carrier |
| US4735804A (en) | 1985-05-10 | 1988-04-05 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| DE3518844A1 (de) | 1985-05-24 | 1986-11-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen | Keramischer verbundwerkstoff |
| US4758436A (en) | 1985-05-29 | 1988-07-19 | Merck & Co., Inc. | Drug delivery device which can be retained in the stomach for a controlled period of time |
| US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| US4861598A (en) | 1986-07-18 | 1989-08-29 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
| USRE34990E (en) | 1986-08-07 | 1995-07-04 | Ciba-Geigy Corporation | Oral therapeutic system having systemic action |
| ES2039287T3 (es) | 1987-01-14 | 1993-09-16 | Ciba-Geigy Ag | Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles. |
| US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
| US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
| IL87710A (en) | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
| US5002772A (en) | 1988-05-31 | 1991-03-26 | Pfizer Inc. | Gastric retention system for controlled drug release |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5007790A (en) | 1989-04-11 | 1991-04-16 | Depomed Systems, Inc. | Sustained-release oral drug dosage form |
| US5217712A (en) | 1989-09-20 | 1993-06-08 | Merck & Co., Inc. | Bioerodible thermoset elastomers |
| US5047464A (en) | 1989-09-20 | 1991-09-10 | Merck & Co., Inc. | Bioerodible thermoset elastomers |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5273758A (en) | 1991-03-18 | 1993-12-28 | Sandoz Ltd. | Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| JP3140465B2 (ja) | 1992-09-18 | 2001-03-05 | 山之内製薬株式会社 | ハイドロゲル徐放性製剤 |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6287598B1 (en) | 1993-05-28 | 2001-09-11 | Alza Corporation | Method for providing sustained antiepileptic therapy |
| US5532003A (en) | 1994-01-18 | 1996-07-02 | Alza Corporation | Pentoxifylline therapy |
| DE4406424A1 (de) | 1994-02-28 | 1995-08-31 | Bayer Ag | Expandierbare Arzneiformen |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| ZA953078B (en) | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| EP0758244B2 (en) | 1994-05-06 | 2008-02-13 | Pfizer Inc. | Controlled-release dosage forms of azithromycin |
| US5698224A (en) | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6491945B1 (en) | 1994-09-16 | 2002-12-10 | Alza Corporation | Hydrocodone therapy |
| US5718700A (en) | 1994-09-20 | 1998-02-17 | Alza Corporation | Exit means in dosage form |
| US5614578A (en) | 1994-10-28 | 1997-03-25 | Alza Corporation | Injection-molded dosage form |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| MY113429A (en) | 1995-02-28 | 2002-02-28 | Univ Temple | Controlled release tablet containing swellable polyethylene oxide |
| US5945125A (en) | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
| US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
| US5695781A (en) | 1995-03-01 | 1997-12-09 | Hallmark Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers |
| AU5652796A (en) | 1995-04-14 | 1996-10-30 | Pharma Pass Llc | Solid compositions containing polyethyleneoxide and a non-am orphous active principle |
| US5736159A (en) | 1995-04-28 | 1998-04-07 | Andrx Pharmaceuticals, Inc. | Controlled release formulation for water insoluble drugs in which a passageway is formed in situ |
| US5674895A (en) | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
| US5912268A (en) | 1995-05-22 | 1999-06-15 | Alza Corporation | Dosage form and method for treating incontinence |
| US5817335A (en) | 1995-05-26 | 1998-10-06 | Alza Corporation | Osmotic device with high drug loading and delayed activation of drug delivery |
| GB9523752D0 (en) | 1995-11-21 | 1996-01-24 | Pfizer Ltd | Pharmaceutical formulations |
| US5783212A (en) | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
| IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
| EP0914097B1 (en) | 1996-03-12 | 2002-01-16 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| ZA97976B (en) | 1996-04-05 | 1997-08-18 | Alza Corp | Uniform drug delivery theraphy. |
| WO1997047285A1 (en) | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| SE9603667D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
| US5837379A (en) | 1997-01-31 | 1998-11-17 | Andrx Pharmaceuticals, Inc. | Once daily pharmaceutical tablet having a unitary core |
| US6057373A (en) | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
| CA2290624C (en) | 1997-06-06 | 2006-12-05 | John W. Shell | Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| AU8643698A (en) | 1997-08-01 | 1999-02-22 | Elan Corporation, Plc | Controlled release pharmaceutical compositions containing tiagabine |
| PT1003476E (pt) | 1997-08-11 | 2005-05-31 | Alza Corp | Forma de dosagem de agente activo de libertacao prolongada adaptada para retencao gastrica |
| US6514530B2 (en) | 1997-09-09 | 2003-02-04 | Alza Corporation | Dosage form comprising means for changing drug delivery shape |
| IT1295271B1 (it) | 1997-10-03 | 1999-05-04 | Chiesi Farma Spa | Monolita contenente uno o piu'farmaci costituito da tre strati a meccanismo di rilascio differenziato |
| US6337091B1 (en) | 1997-10-27 | 2002-01-08 | Temple University - Of The Commonwealth System Of Higher Education | Matrix for controlled delivery of highly soluble pharmaceutical agents |
| DK1035834T3 (da) | 1997-12-05 | 2002-07-08 | Alza Corp | Osmotisk doseringsform omfattende en første og anden coating |
| US5916595A (en) | 1997-12-12 | 1999-06-29 | Andrx Pharmaceutials, Inc. | HMG co-reductase inhibitor |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6294583B1 (en) * | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| WO1999036064A2 (en) | 1998-01-13 | 1999-07-22 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| FR2775188B1 (fr) | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| US6365183B1 (en) | 1998-05-07 | 2002-04-02 | Alza Corporation | Method of fabricating a banded prolonged release active agent dosage form |
| US6635281B2 (en) | 1998-12-23 | 2003-10-21 | Alza Corporation | Gastric retaining oral liquid dosage form |
| US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
| CA2389236A1 (en) | 1999-11-02 | 2001-05-10 | Depomed, Inc. | Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| ES2270982T3 (es) | 2000-02-04 | 2007-04-16 | Depomed, Inc. | Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero. |
| US6488962B1 (en) | 2000-06-20 | 2002-12-03 | Depomed, Inc. | Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| US6451808B1 (en) | 2000-10-17 | 2002-09-17 | Depomed, Inc. | Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| MXPA03003895A (es) | 2000-10-30 | 2003-07-28 | Euro Celtique Sa | Formulaciones de hidrocodona de liberacion controlada. |
| US6462084B1 (en) * | 2001-05-14 | 2002-10-08 | Brookhaven Science Associates, Llc | Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG |
| MXPA03012041A (es) | 2001-07-04 | 2004-03-26 | Sun Pharmaceutical Ind Ltd | Sistema de administracion controlada de farmacos de retencion gastrica. |
| CA2409552A1 (en) | 2001-10-25 | 2003-04-25 | Depomed, Inc. | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| US7612112B2 (en) | 2001-10-25 | 2009-11-03 | Depomed, Inc. | Methods of treatment using a gastric retained gabapentin dosage |
| JP2005508358A (ja) | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| TWI312285B (en) | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| DE10208335A1 (de) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Arzneiform und Verfahren zu ihrer Herstellung |
| GB0214013D0 (en) | 2002-06-18 | 2002-07-31 | Euro Celtique Sa | Pharmaceutical product |
| RU2284814C1 (ru) | 2005-04-08 | 2006-10-10 | Государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Министерства здравоохранения Российской Федерации" | Способ лечения оптического неврита при оптикохиазмальном арахноидите в стадии ремиссии |
| HUE043365T2 (hu) | 2006-01-18 | 2019-08-28 | Intec Pharma Ltd | Kiadóberendezés szer orális bevételéhez |
| WO2007093999A1 (en) | 2006-02-15 | 2007-08-23 | Intec Pharma Ltd. | A gastro-retentive system for the delivery of macromolecules |
| US7858611B2 (en) | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| US20100081672A1 (en) | 2006-12-07 | 2010-04-01 | Schering Corporation | Ph sensitive matrix formulation |
| DE102007009242A1 (de) | 2007-02-22 | 2008-09-18 | Evonik Röhm Gmbh | Pellets mit magensaftresistenter Wirkstoff-Matix |
| US20110195974A1 (en) | 2007-08-24 | 2011-08-11 | Rekha Bansal | Methods of treating inflammatory conditions with adrenergic antagonists |
| BRPI0914080A2 (pt) * | 2008-10-08 | 2015-10-27 | Bioplus Life Sciences Pvt Ltda | "sistema de liberação de dosagem controlada, método de administração e processo de preparação do mesmo" |
| JP2012510987A (ja) | 2008-12-04 | 2012-05-17 | インテック ファーマ リミテッド | ザレプロン胃内滞留性薬剤送達システム |
| CA2781830C (en) * | 2009-02-12 | 2018-03-27 | Indiana University Research & Technology Corporation | Materials and methods for treating developmental disorders including comorbid and idiopathic autism |
| JP5714562B2 (ja) | 2010-02-22 | 2015-05-07 | 第一三共株式会社 | 経口用徐放性固形製剤 |
| NZ603531A (en) | 2010-05-11 | 2014-08-29 | Cima Labs Inc | Alcohol-resistant formulations |
| MX346203B (es) | 2010-09-28 | 2017-03-09 | Depomed Inc | Formas de dosificacion retentivas gastricas para liberacion prolongada de acamprosato en el tracto gastrointestinal superior. |
| US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| BR112014013374B1 (pt) * | 2011-12-02 | 2022-10-11 | Synchroneuron Inc | Comprimidos de acamprosato e usos de acamprosato referência cruzada aos pedidos relacionados |
| TR201112014A2 (tr) | 2011-12-05 | 2012-11-21 | Hi̇dromek-Hi̇droli̇k Ve Mekani̇k Maki̇na İmalat Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Değişken mekanik avantaj sağlayan fren pedal sistemi. |
| WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
-
2014
- 2014-06-05 WO PCT/US2014/041186 patent/WO2014197744A1/en not_active Ceased
- 2014-06-05 EP EP20193333.0A patent/EP3878445A3/en not_active Withdrawn
- 2014-06-05 JP JP2016518015A patent/JP2016520653A/ja active Pending
- 2014-06-05 US US14/421,806 patent/US10166207B2/en active Active
- 2014-06-05 CN CN201480032376.9A patent/CN105431144A/zh active Pending
- 2014-06-05 CA CA2914365A patent/CA2914365C/en active Active
- 2014-06-05 EP EP14808367.8A patent/EP3003297A4/en not_active Ceased
-
2015
- 2015-05-21 US US14/718,797 patent/US20150250746A1/en not_active Abandoned
- 2015-12-04 US US14/960,119 patent/US20160081938A1/en not_active Abandoned
-
2019
- 2019-03-19 JP JP2019050939A patent/JP6824314B2/ja active Active
- 2019-04-04 US US16/374,850 patent/US20200061003A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520653A5 (https=) | ||
| TWI324075B (en) | Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract | |
| JP5241228B2 (ja) | 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠 | |
| CN105431144A (zh) | 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合 | |
| EP2105133A1 (en) | Intragastric floating-type levodopa sustained-release preparation | |
| KR101156054B1 (ko) | 안정한 에페리손 함유 서방성 의약조성물 | |
| JP2017510607A5 (https=) | ||
| EP2405900A2 (en) | A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants | |
| JP6735020B2 (ja) | アマンタジン組成物を投与する方法 | |
| RU2020107732A (ru) | Схема дозирования модулятора s1p с немедленным высвобождением | |
| US20150132378A1 (en) | Multilayered dosage form | |
| BRPI0711871A2 (pt) | composições farmacêuticas para liberação sustentada de fenilefrina | |
| US20260069543A1 (en) | Controlled-release tablet of ibuprofen and its use for relieving pain | |
| JP2006515299A (ja) | 非ステロイド性抗炎症薬、充血除去薬および抗ヒスタミン薬の組成物 | |
| RS60240B1 (sr) | Postupci i kompozicije za lečenje depresije korišćenjem ciklobenzaprina | |
| WO2024160030A1 (zh) | 一种组合物及其在制备治疗神经性疼痛药物中的应用 | |
| RU2671399C2 (ru) | Композиции акампросата, способы их применения и содержащие их комбинации | |
| JP5403935B2 (ja) | 経口用の慢性疼痛予防または治療剤 | |
| JP2006528604A5 (https=) | ||
| JP7673210B2 (ja) | 皮膚放射線傷害の予防及び治療のための組成物及び方法 | |
| CA2625835A1 (en) | Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion | |
| TW200800155A (en) | Gastric retentive gabapentin dosage forms and methods for using same | |
| US20060105036A1 (en) | Threo-dops controlled release formulation | |
| JP4384435B2 (ja) | くしゃみ抑制組成物 | |
| CN101002755A (zh) | 一种组合脉冲释放制剂及其制备方法 |